Study of AZD5863 for Advanced Solid Tumors
Phase 1/2
280
about 3.9 years
18+
3 sites in FL, MN, NY
What this study is about
This trial is testing a new treatment called AZD5863 in adults with advanced or metastatic solid tumors. The goal is to see if this medication is safe, well-tolerated, and effective against cancer.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take AZD5863
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You are randomly assigned, but you will know your treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Objective Response Rate (ORR), The number of patients with adverse events, The number of patients with adverse events of special interest, The number of patients with dose-limiting toxicity (DLT), as defined in the protocol., The number of patients with serious adverse events
Secondary: Disease Control Rate (DCR), Duration of response (DoR), Objective Response Rate (ORR), Overall Survival (OS), Pharmacokinetics of AZD5863: Area Under the concentration-time curve (AUC), Pharmacokinetics of AZD5863: Clearance, Pharmacokinetics of AZD5863: Maximum plasma concentration of the study drug (Cmax), Pharmacokinetics of AZD5863: Terminal elimination half-life (t 1/2)